Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ys110
- Development stage
- Phase 2
- Lead developer
- Kissei Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
YS110 is a recombinant humanized IgG1 monoclonal antibody that targets CD26 (also known as dipeptidyl peptidase IV, DPP4), a cell surface glycoprotein expressed on certain tumor cells. Upon binding to CD26, YS110 inhibits its activity and induces internalization of the CD26-YS110 complex, leading to cell cycle arrest, lysis, and inhibition of growth in CD26-positive tumor cells. The drug has demonstrated antitumor activity in preclinical models and was generally well tolerated in early-phase clinical trials. YS110 has been primarily developed for the treatment of malignant pleural mesothelioma and other solid tumors expressing CD26[1][2][3][5]. The originator is Ys Therapeutics.
- Brand names
- YS110YS-110YS 110
- Other names
- humanized anti-cd26 monoclonal antibodyanti-cd26 monoclonal antibodyanti-cd-26 monoclonal antibodyanti-cd 26 monoclonal antibodyys110ys-110ys 110
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)
Beyond the preview
Go deeper on ys110.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ys110.